Select therapeutic use:
Indications for BRIDION:
To reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.
Give as single bolus inj over 10 secs. Rocuronium and vecuronium: 4mg/kg if spontaneous recovery of the twitch response has reached 1–2 post-tetanic counts (PTC) with no twitch responses to train-of-four (TOF) stimulation. 2mg/kg if spontaneous recovery has reached the reappearance of the second twitch in response to TOF stimulation. Rocuronium only: 16mg/kg if reversal needed soon (approx. 3mins) after given a single rocuronium 1.2mg/kg dose. Re-administration of neuromuscular blockers post-reversal: see full labeling.
≤17yrs: not established.
Do not use to reverse blockade induced by agents other than rocuronium or vecuronium. Should be administered by trained healthcare providers. Have treatment for anaphylaxis readily available. Maintain ventilation and patent airway; monitor until recovery. Monitor for hemodynamic changes and administer anticholinergic agents (eg, atropine) if significant bradycardia observed. Risk of neuromuscular blockade recurrence; see full labeling. Coagulopathies. Signs of light anesthesia. Severe renal impairment (CrCl <30mL/min), dialysis: not recommended. Hepatic impairment with coagulopathy or severe edema. Elderly. Pregnancy. Nursing mothers.
Recovery could be delayed with concomitant toremifene. May antagonize progestogen; if hormonal contraceptive taken on the same day as Bridion, must use additional non-hormonal contraceptive or back-up method (eg, condom, spermicide) for next 7 days. Increased bleeding risk with anticoagulation therapy, thromboprophylaxis drugs other than heparin and LMWH. May interfere with progesterone assay. Physically incompatible with verapamil, ondansetron, ranitidine.
Modified gamma cyclodextrin.
Vomiting, pain, nausea, hypotension, headache; hypersensitivity, marked bradycardia, increases in aPTT and PT/INR.
Single-dose vials (2mL, 5mL)—10